Online inquiry

IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1083MR)

This product GTTS-WQ1083MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets SLAMF7 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001282588.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57823
UniProt ID Q9NQ25
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ1083MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ694MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA A-1230717
GTTS-WQ11944MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ3827MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, BCD-054(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BCD-054
GTTS-WQ9387MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ12216MR IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MOXR-0916
GTTS-WQ4332MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BIW-8405
GTTS-WQ12719MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ1296MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABT-555
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW